Terumo — Investor Presentation (July 2011)

5 slides from Terumo's investor presentation, Jul 28, 2011

Slide 1: Growth Strategy Gains Momentum
Growth Strategy Gains Momentum Terumo Corporation President & Representative Director Yutaro Shintaku July 28, 2011
Slide 2: Hands-on Approach for Unifying CaridianBCT
Hands-on Approach for Unifying CaridianBCT 2011/7/28 Terumo Corporation 2/5
Slide 3: New Opportunities with BCT Technologies
New Opportunities with BCT Technologies The first autologous cellular immunotherapy (Cancer vaccine) in business <Example: Prostate cancer> U.S. cancer vaccine company FDA approval in Apr, 2010 CaridianBCT Spectra® Collect blood containing Derive dendritic Introduce antigen onto Administer to lots o
Slide 4: Further Potential
Further Potential Ce ll ular Imm un othe ra p y Cell Therapeutic Expansion Aphaeresis Utilizing cells and growth factors, Myocardial Regeneration into Regenerative Medicine Myocardial patch mi a he r y isc a o r ona chemi t o f c m b is t m en nic li a Tre & Chro Cell deriving 2011/7/28 Terumo Corpo
Slide 5: IR Contact
IR Contact TERUMO Corporation Corporate Communication (IR) Dept. E-mail: kouhou_terumo01@terumo.co.jp Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo